908 Devices Posts 18% Revenue Growth in 2025, Achieves Adjusted EBITDA Positivity
Event summary
- 908 Devices reported $56.2 million in full-year 2025 revenue, up 18% YoY, driven by FTIR product revenue growth.
- Q4 2025 revenue hit $17.4 million, a 21% increase from Q4 2024, with adjusted gross margin improving by 530 basis points.
- The company achieved positive adjusted EBITDA of $0.7 million in Q4 2025, marking a significant turnaround from a $4.0 million loss in Q4 2024.
- Recurring revenue grew 22% YoY to $19.5 million, representing 35% of total 2025 revenues.
- 908 Devices ended 2025 with $113.0 million in cash and no debt, reflecting a strong balance sheet.
The big picture
908 Devices' strong financial performance in 2025 highlights its strategic focus on purpose-built handheld chemical analysis tools for health, safety, and defense applications. The company's ability to achieve adjusted EBITDA positivity and maintain a robust balance sheet positions it well to capitalize on growing demand in critical sectors. The shift towards recurring revenue models also underscores a broader industry trend towards subscription-based services in the tech and defense sectors.
What we're watching
- Revenue Growth
- Whether 908 Devices can sustain its 15-20% revenue growth guidance for 2026 amid increasing competition in the handheld chemical analysis market.
- Margin Expansion
- The pace at which the company can further improve its adjusted gross margin, which reached 57% in Q4 2025.
- Recurring Revenue
- How the company's focus on recurring revenue, which now represents 35% of total revenues, will impact long-term customer retention and financial stability.
Related topics